reports
Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela Provides Business Update and Reports Q1 2024 Financial Results MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. Q1 2024 and recent Highlights: Clinical Announced revised timing for the interim data analysis for its ongoing ASPIRE trial, ...
Consolidated Water Reports First Quarter 2024 Revenue up 21% to $39.7 ...
Consolidated Water Reports First Quarter 2024 Revenue up 21% to $39.7 Million, Driving Net Income from Continuing Operations of $6.9 Million or $0.43 Diluted EPS GEORGE TOWN, Cayman Islands, May 15, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, reported results for the first quarter ended March 31, 2024. All comparisons are to the same prior year period unless otherwise noted. The company will hold a conference call at 11:00 a.m. Eastern time tomorrow to discuss the results (see dial...
Hawkins, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results
Hawkins, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results ROSEVILLE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN), a leading specialty chemical and ingredients company, today announced fourth quarter and full-year results for its fiscal year ended March 31, 2024. Fourth Quarter Fiscal Year 2024 Highlights: Fourth quarter sales of $223.0 million, down 2% compared to the same quarter in the prior year, with Water Treatment segment sales growth of 21% over the same quarter in the prior year.Gross profit of $45.5 million, a 27% increase over the same quarter ...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Pr...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. “We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sa...
Polar Power Reports First Quarter 2024 Financial Results
Polar Power Reports First Quarter 2024 Financial Results GARDENA, CA, May 15, 2024 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup, and solar hybrid DC power solutions, reports its financial results for the first quarter of 2024. Q1 2024 Financial Highlights ●Net sales of $1.8 million compared to $4.2 million in the same period in 2023●Operating expenses of $1.6 million compared to $1.7 million in the same period in 2023●Net loss was $2.1 million, or $(0.12) per basic and diluted share, compared to a net loss of...
Unusual Machines Issues Letter to Shareholders
Unusual Machines Issues Letter to Shareholders CEO Allan Evans shares post-IPO achievements and provides insight into the Company’s strategic expansion into defense sector ORLANDO, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- Unusual Machines, Inc. (NYSE American: UMAC) (“Unusual Machines” or the “Company”), a drone and drone components manufacturer, today announced it filed its 10-Q with the U.S. Securities and Exchange Commission for the first quarter of 2024 and provided the following letter to its shareholders from CEO Allan Evans. Dear Shareholders, We are excited to present our first...
Ingredion Incorporated Declares Quarterly Dividend of $0.78 per Share
Ingredion Incorporated Declares Quarterly Dividend of $0.78 per Share WESTCHESTER, Ill., May 15, 2024 (GLOBE NEWSWIRE) -- Today, the board of directors of Ingredion Incorporated (NYSE: INGR) declared a quarterly dividend of $0.78 per share on the Company’s common stock. The dividend is payable on July 23, 2024, to stockholders of record at the close of business on July 1, 2024. About the CompanyIngredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in nearly 120 countries. With 2023 annual net sale...
Robinhood Markets, Inc. Reports April 2024 Operating Data
Robinhood Markets, Inc. Reports April 2024 Operating Data MENLO PARK, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported select monthly operating data for April 2024: Funded Customers at the end of April were 24.0 million, up approximately 90 thousand from March 2024.Assets Under Custody (AUC) at the end of April were $123.3 billion, down 5% from March 2024. Net Deposits were $4.9 billion in April, translating to a 45% annualized growth rate relative to March 2024 AUC. Over the last twelve months, Net Deposits were $27.4 billion, ...
Envoy Medical Reports First Quarter 2024 Results
Envoy Medical Reports First Quarter 2024 Results The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the first quarter ended March 31, 2024. Financial and Corporate...
Spero Therapeutics Announces First Quarter 2024 Operating Results and ...
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWI...
Snail, Inc. Reports First Quarter 2024 Financial Results
Snail, Inc. Reports First Quarter 2024 Financial Results CULVER CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Snail, Inc. (NASDAQ: SNAL) (“Snail” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, today announced financial results for its first quarter ended March 31, 2024. Tony Tian, Co-Chief Executive Officer commented, “I'm absolutely thrilled and humbled to take the helm as Co-CEO of Snail. This Company has an exceptionally talented team, ground-breaking technologies, and iconic franchises, like ARK, that have fostered pass...
STRATA Skin Sciences Reports First Quarter 2024 Financial Results and ...
STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., May 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the fir...
Biora Therapeutics Provides Corporate Update and Reports First Quarter...
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipelin...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support innovative pipeline through key clinical inflection points BOTHELL, Wash., M...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Finan...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic hea...
Oncocyte Reports First Quarter 2024 Financial Results
Oncocyte Reports First Quarter 2024 Financial Results Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development for FDA submission....
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Pr...
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update — Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on related matter— Site optimization projects near completion— Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery ...
Aqua Metals Advances Circular Supply Chain Strategy with Sierra ARC Bu...
Aqua Metals Advances Circular Supply Chain Strategy with Sierra ARC Buildout, Commercial Partnerships, and $40M Capital Infusion, Reports First Quarter 2024 Results Commences $7M Equity Raise, Signs $33M Non-binding Loan Term Sheet with One of the Worlds’ Largest Private Companies, Initiates Strategic Offtake Agreement with 6K Energy RENO, Nev., May 15, 2024 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling, today reported financial results and provided an operational update, for the first quarter ended March 31, 2024. First ...
Barfresh Provides First Quarter 2024 Results and Business Update
Barfresh Provides First Quarter 2024 Results and Business Update Record Quarterly Revenue and First Positive Adjusted EBITDA In Company History Highlight Strong First Quarter of 2024 Results Revenue Increased 35% Year-Over-Year to $2.8 Million for the First Quarter of 2024 Achieves 41.4% First Quarter of 2024 Gross Margin - Highest Point Since Early 2021 Company Poised to Achieve Highest Annual Revenue in Fiscal Year 2024 and Year-over-Year Margin Improvement Amid Bottling Recovery Efforts, Propelled by Accelerated Customer Wins LOS ANGELES, May 15, 2024...
Leslie’s, Inc. Appoints Maile (Clark) Naylor to Board of Directors
Leslie’s, Inc. Appoints Maile (Clark) Naylor to Board of Directors PHOENIX, May 15, 2024 (GLOBE NEWSWIRE) -- Leslie's, Inc. ("Leslie's" or the “Company”; NASDAQ: LESL), the largest and most trusted direct-to-consumer brand in the U.S. pool and spa care industry, announced that the Company has appointed Maile (Clark) Naylor to its Board of Directors, replacing Eric Kufel, effective May 15, 2024. Ms. Naylor has joined as a Class I Director and member of the Audit and Compensation Committees. Mr. Kufel has resigned from his board duties at Leslie’s to concentrate on his recently appointed ro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.